|
The French-American Chamber of Commerce of San
Francisco
cordially invites you to join them to a:
Life
Science Breakfast
Challenges
and opportunities of biodefense contracts: a road map
Tuesday,
October 3rd 2006
7:30 am - 9:30 am
At
Swissnex
730 Montgomery Street
San Francisco
Breakfast will be served
Swissnex connects the dots in science, education,
art and innovation,
between Switzerland and Western North America
__________________________________________
SPEAKERS
Dr. Heather Koshinsky,
CEO, President and co-founder, Investigen,
Inc.
Dr. Heather Koshinsky, CEO, President
and co-founder. She is a microbial geneticist who previously worked at
the Plant Gene Expression Center and at the University of
Saskatchewan.
She supervised microbiological/molecular biological research projects
involving yeast and bacterial genetics and food safety. Dr. Koshinsky
was also an assistant professor with University of Saskatchewan. She
obtained a B.Sc. in Biology and a Ph.D. in Applied Microbiology from
University of Saskatchewan, and a Certificate of Business
Administration from University of California, Berkeley Extension.
Piers Whitehead
VaxGen, Vice President, Corporate
and Business Development
Piers Whitehead is currently Vice
President of Corporate and Business Development at Vaxgen. In this
position he has been deeply involved in the $877.5 millions Bioshield
contract Vaxgen was awarded in November 2004 to supply 75 million
doses of anthrax vaccine for civilian defense.
 He was formerly the vice president
and head of Mercer Management Consulting’s San Francisco office. There
he led marketing, strategy and manufacturing projects, with an
emphasis on global health and vaccines,
for clients that included the Global Alliance for Vaccines and
Immunization, UNICEF and several private sector clients.
During his 11 years with Mercer, Mr. Whitehead gained international
prominence for his wide-ranging analysis of the biologics,
pharmaceutical, global health and vaccine markets. His reports on the
state of international vaccine development, including the analysis of
manufacturing economics for the developing world, have become standard
references for the field.
Prior to joining Mercer he was a manager with London-based investment
bank Robert Fleming Securities Ltd. There he led a team of seven
analysts covering the European goods sector. Mr. Whitehead graduated
from Oriel College in Oxford, England, receiving an M.A. in Classics,
with honors, and a B.A. in Ancient and Modern Philosophy, with honors.
MODERATOR
Fred Dorey:
special counsel
in the Life Sciences practice group of the
Cooley Godward Business department
 Mr.
Dorey represents a range of biotechnology, instrumentation and other technology
companies at various stages of development from start-up and incorporation
through licensing, corporate partnering and major collaboration transactions.
He also has extensive experience negotiating clinical trial, sponsored research
and intellectual property agreements. In addition, Mr. Dorey advises a number of
major foundations, research institutions, and individuals regarding their
participation in biomedical research endeavors, including investment, licensing
and commercialization activities.
Before joining the Firm, Mr. Dorey was the first president of the Bay Area
Bioscience Center, a consortium of research universities, biotechnology
companies and local governments organized to support bioscience development
in Northern California. He also served as part-time in house counsel
for several biotech companies including Tularik, Geron and Shaman.
Previously, he had served as general counsel and corporate secretary for
British Petroleum in San Francisco, where he was chief legal advisor for the
Fortune 500-sized subsidiary that handled all BP oil exploration and
production in the United States.
He has also served as a regulatory enforcement lawyer and assistant office
director for the Department of Energy in Washington DC. Mr. Dorey received a
JD from the University of Southern California Law Center, where he was
president of the Student Bar Association. Before law school he served
as a White House Intern in the office of the Director of the Peace Corps in
Washington DC. He received a BS in Engineering from University of
California, Los Angeles. Mr. Dorey currently serves as a director of the
American Liver Foundation, the World Affairs Council of Northern California,
the Bay Area Bioscience Center, the San Francisco Boys Chorus and the
National Kidney Foundation of Northern California. He is also a
director of a privately held research instrumentation company.
He is a member of the State Bar of California and the District of Columbia Bar.
Please click here for registration
REGISTRATION
Registration price valid until 5-days
Prior to the
event
date
Cancellations must be made 5-days prior to the event date
Any cancellation within a 5-day period of the scheduled date will
not be refunded
Name of guest will be kept at
the door
$20 for members $25 for
non-members
$30 at the door
Or please mail or fax the reservation Card below
Reservation Card - 05/11 Life Science Breakfast
Please reserve ___ seat (s) at $20 per person (for Members).
Please reserve ___ seat (s) at $25 per person (for Non Members).
Name________________________________________________________________
Company______________________________________________________________
Address_______________________________________________________________
Email address______________________________________________ for
confirmation
Phone number __________________________________________________________
Visa/MC Number_________________________________________________________
Expires________Signature_________________________________________________
Please make checks payable to FACCSF
Please, fax this coupon to
French-American Chamber of Commerce
703 Market Street, Suite 450, San Francisco, CA
94103
Tel: 415 442 4717 / Fax 415 442 4621
|
Shauna Farr-Jones helps life science
companies raise money via government grants and contracts. She
provides proposal writing and strategic editing services to companies
and universities in a variety of technology and therapeutic areas.
Previously, she was an industry analyst at BioCentury Publications
Inc., the leading biotechnology business newsletter, where she
analyzed and wrote about strategic market and technology issues
affecting biotechnology companies. She has conducted market research
for HighTech Business Decisions on numerous drug discovery
technologies. She was a post-doctoral fellow and research faculty
member at the University of California, San Francisco, where she did
research on protein structure determination. She earned a B.Sc. in
Chemistry from Southampton University, UK, a Ph.D. in Biochemistry
from Tufts University in Boston, and Certificates in Marketing and
Finance from University of California, Berkeley Extension.